Physician profile
Peter Lipsy
NPI 1124386669
$2,820.19
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $356 · 2021: $1,125 · 2022: $828 · 2023: $301 · 2024: $34.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.28 | 2021-2023 | |
| Novo Nordisk INC | $381.49 | 2020-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $156.87 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $148.63 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $144.48 | 2019-2022 | |
| Lilly USA, LLC | $131.24 | 2020-2023 | Mounjaro, Trulicity |
| Amgen INC. | $121.47 | 2020-2022 | |
| Pfizer INC. | $107.55 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.07 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $76.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $72.51 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.17 | 2020-2022 | |
| Daiichi Sankyo INC. | $64.35 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $64.22 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $63.36 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $57.71 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.59 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $45.99 | 2020-2023 | Austedo Xr |
| Vifor Pharma, INC. | $40.87 | 2019-2020 | |
| Corcept Therapeutics | $34.95 | 2022-2023 | Korlym |
| Upsher-Smith Laboratories LLC | $34.08 | 2021 | |
| Jazz Pharmaceuticals INC. | $29.41 | 2021 | |
| Allergan, INC. | $27.17 | 2020 | |
| Merck Sharp & Dohme LLC | $26.00 | 2019-2021 | |
| Shield Therapeutics INC | $22.38 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $18.32 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.31 | 2021 | |
| Exact Sciences Corporation | $16.70 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $16.30 | 2021 | |
| Abbott Laboratories | $16.17 | 2021 | |
| Glaxosmithkline, LLC. | $12.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.35 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.71 | 2022 | |
| Lifescan, INC. | $11.55 | 2020 | |
| Sumitomo Pharma America, INC. | $8.80 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lipsy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.